NEW: We have just launched DHbriefs to offer a series of research briefs covering specific digital health market niches. Click here for more information.

Senseonics launches the Eversense Bridge Program in the U.S.

The company's implantable system is the only long-term CGM that lasts up to 90 days; it is now available for $99 plus the cost of the sensor placement.

eversense-cgm.jpg

Senseonics launches the Eversense Bridge Program in the U.S.

Senseonics is launching the Eversense Bridge Program in the U.S. offering its implantable Eversense CGM (continuous glucose monitoring) System — the only long-term CGM that lasts up to 90 days — for $99 plus the cost of the sensor placement by the healthcare provider.

“The Eversense Bridge Program is an important strategic initiative with the goal of providing access to eligible patients who have high out-of-pocket costs, are waiting for a favorable coverage policy, or have been denied insurance coverage for Eversense,” Tim Goodnow, President and CEO of Senseonics, said in a statement. “Insurance companies unfamiliar with the newest approved diabetes technology may deny coverage for a wide range of insured patients who have come forward demanding this technology. We developed this program to reduce barriers for patients who seek access to this technology right away. Every patient who qualifies for the program will now have improved access to this innovative diabetes management technology.”

The Eversense Bridge Program is designed to assist patients with confirming their insurance benefits, obtaining pre-authorizations before the sensor placement and working with their healthcare provider’s office to help patients with the appeals of denied claims. From start to finish, the Eversense Bridge Program has been created to help the healthcare providers and patients have easier access to Eversense CGM.

The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. Unlike traditional CGMs, Eversense is the first and only implantable CGM sensor in the United States and has the longest duration of up to 90 days.

Said smart transmitter provides discreet, on-body vibratory alerts for high and low glucose and can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.

Patients who are interested in getting started on Eversense through the Eversense Bridge Program can sign up from here.

Links: Source

Leave a Reply

NEW: DHbriefs offers series of research briefs covering specific digital health market niches. Click here for more information.
Top